Affichage 11 à 16 des 16 essais cliniques
1 | 2 |
ESSAIS CLINIQUES
    No essai
    ClinicalTrials.gov ID
Phase Coordonnateur(rice)
(EN) A Multi-Country, Real-World Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients Diagnosed With Myelofibrosis Through Chart Review
    METER
    NCT05444972
     Actif en recrutement
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
Un registre exhaustif et observationnel des néoplasies myéloprolifératives dans la province du Québec (Registre des NMP)
    CINC424BCA04T
     Actif en recrutement
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
Autres Caroline Chagnon
514-338-2222 poste 2818
(EN) A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as Second Line Therapy for Essential Thrombocythemia
    SURPASS ET
    NCT04285086
     Actif en recrutement
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
Sarah Barnier
514-340-8222 poste 26394
(EN) A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/?L)
    PACIFICA
    NCT03165734
     Actif en recrutement
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
Sarah Barnier
514-340-8222 poste 26394
(EN) A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
    INCA 33989-101
    NCT05936359
     Actif en recrutement
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
Julie Trinh Lu
514-252-3400 poste 3336
(EN) A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis
    TRANSFORM-2
    NCT04468984
     Actif en recrutement
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS
Pierre Bédard
418-835-7121
1 | 2 |